Price movement over the last 24 hours
Archer-Daniels-Midland Co vs Zimmer Biomet Holdings Inc — how do they compare? Archer-Daniels-Midland Co trades at $79.94 (market cap $37.69B), while Zimmer Biomet Holdings Inc trades at $88.44 (market cap $17.30B). The key difference: Archer-Daniels-Midland Co is far larger — about 2.2× Zimmer Biomet Holdings Inc's market cap, and Archer-Daniels-Midland Co pays the higher dividend (2.66%). Which is the better fit depends on your goals.
| ADM | ZBH | |
|---|---|---|
Market Cap | $37.69B | $17.30B |
Sector | Consumer Staples | Health |
52-Week High | $84.11 | $107.71 |
52-Week Low | $53.54 | $79.58 |
Enterprise Value | $47.72B | $24.34B |
Dividend Yield | 2.66% | 1.07% |
Signals from Pluang's Aura AI — not financial advice
ADM trades at $78.20, up 1.84% recently, with a bullish technical signal from moving averages and a consensus analyst price target of $78.00. The company has beaten EPS estimates for three consecutive quarters, though revenue has declined from $101.6B in 2022 to $80.3B in 2025. Net cash flow improved to $1.58B in 2025, reversing negative trends from prior years, while the stock shows a P/E of 34.79 and P/S of 0.47, indicating mixed valuation signals.
Outlook is cautiously optimistic with strong cash flow and earnings beats, but risks include declining revenue margins and competitive pressures. The stock offers value characteristics with a low P/S ratio, yet investors face headwinds from narrowing profit margins and global trade volatility in agricultural markets.
Zimmer Biomet (ZBH) trades at $89.41, up 2.22% with a bullish technical signal and consistent earnings beats. The stock shows strong fundamentals with 70% gross margins and revenue growth to $8.23B in 2025, though net margins compressed to 8.56%. Recent developments include a $140M acquisition and plans to hire 500 tech employees in India, supporting growth initiatives. Valuation metrics appear reasonable with P/E of 23.25 and P/S of 2.11.
ZBH offers moderate upside to the $98.33 consensus target with analyst sentiment mixed (43% buy, 50% hold). Key risks include rising debt levels (debt-to-asset ratio increased to 32.57% in 2025) and margin pressure. The company's $1B share repurchase program and dividend provide shareholder returns, but execution on growth initiatives remains critical for sustained outperformance.
Trailing returns across standard periods
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →